Veru enrolls first patient in phase 2 clinical trial of veru-100, novel long-acting gnrh antagonist decapeptide injection formulation, for the treatment of hormone sensitive advanced prostate cancer

--veru-100 formulated to address the clinical limitations of currently available androgen deprivation therapy-- --the phase 2 clinical trial is expected to be completed by 2h calendar 2021--
VERU Ratings Summary
VERU Quant Ranking